CLDXCelldex Therapeutics, Inc.
In Vitro & In Vivo Diagnostic Substances
- Revenue
- $2M
- 78% YoY
- Operating margin
- -18599.8%
- 569% YoY
- EBITDA
- −$284M
- 48% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired23× of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear12% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $5M | $2M | $7M | $7M | $2M | 78% |
| Operating income | −$71M | −$115M | −$155M | −$195M | −$287M | 47% |
| Net income | −$71M | −$112M | −$141M | −$158M | −$259M | 64% |
| Operating cash flow | −$61M | −$104M | −$107M | −$158M | −$211M | 34% |
| Capex | $1M | $2M | $2M | $2M | $3M | 41% |
| Stock-based comp | $9M | $16M | $24M | $34M | $36M | 5.8% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $5M | $5M | 155 | 201 |
| FY2024 | $9M | $76K | 144 | 156 |
| FY2023 | $8M | $4M | 226 | 144 |
| FY2022 | $5M | $10M | 254 | 139 |
| FY2021 | $6M | $14M | 221 | 124 |